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ABSTRACT
Mesenchymal stemcells andmultipotent adult progenitor cells (MAPCs) havebeenproposedasnovel
therapeutics for solid organ transplant recipients with the aim of reducing exposure to pharmacolog-
ical immunosuppressionand its sideeffects. In thepresent study,wedescribe the clinical courseof the
first patient of the phase I, dose-escalation safety and feasibility study, MiSOT-I (Mesenchymal Stem
Cells in SolidOrganTransplantationPhase I). After receiving a living-related liver graft, thepatientwas
given one intraportal injection and one intravenous infusion of third-party MAPC in a low-dose phar-
macological immunosuppressive background. Cell administration was found to be technically feasi-
ble; importantly,we foundnoevidenceof acute toxicity associatedwithMAPC infusions. STEMCELLS
TRANSLATIONAL MEDICINE 2015;4:899–904
SIGNIFICANCE
Liver transplantation is the only definitive treatment for liver failure. However, in order to prevent
rejection of the graft, patients must receive lifelong pharmacological immunosuppression, which
itself causes clinically significant side effects. This study provides preclinical evidence thatmesenchy-
mal stem cells (MSCs) and multipotent adult progenitor cells (MAPCs) can prolong allogeneic solid
organ transplant survival in animals by switching the host response toward operational tolerance.
To examine the safety and feasibility of MAPC therapy in patients receiving a living-related or
dead-before-donation unrelated donor liver graft, theMiSOT-I (Mesenchymal Stem Cells in Solid Or-
gan Transplantation Phase I) trial was designed. The first study patient, a 27-year-old male with liver
cirrhosis of unknown etiology, received a living-related adult right liver graft from his brother. MAPC
administration in both the operating room (day 0) and intensive care unit (day 2) was feasible, and no
evidence was seen of acute complications associated with the cell infusion. The absence of any acute
clinical complications of cell infusion is reassuring for the future administration of MAPCs.
INTRODUCTION
Liver transplantation is the only definitive
treatment for liver (function) failure. Grafting
of an allogeneic organ usually requires signifi-
cant immunosuppression of the host. Mesen-
chymal stem cells (MSCs) [1] and multipotent
adult progenitor cells (MAPCs) [2] have been
proposed as immune-active treatments for
multiple indications. The aim of cell-based im-
munosuppression in transplantation is to
reduce the need for long-term pharmacologi-
cal immunosuppression and the associated
deleterious side effects. We [3], and others
[4], have provided preclinical evidence that
MSCs and MAPCs can prolong allogeneic solid
organ transplant survival in animals by switch-
ing the host response toward operational tol-
erance [5].
In the present study, we present a clinical
case report from the MiSOT-I (Mesenchymal
Stem Cells in Solid Organ Transplantation Phase I)
trial [6, 7]. Thepatient,a27-year-oldmalewith liver
cirrhosis of unknown etiology, received a living-
related adult right liver graft from his brother.
The recipient’s medical history included an episode
of atrial fibrillation. In addition, the recipient was
of the rare Lu(b)-negative blood type, with high
serum anti-Lu(b) antibody titers [donor blood type
0, rhesus-negative, Lu(b)+].













93053, Germany. Telephone: 49-
941-944-6812; E-Mail: marc.
dahlke@ukr.de
Received January 14, 2015;
accepted for publication April 13,






STEM CELLS TRANSLATIONAL MEDICINE 2015;4:899–904 www.StemCellsTM.com ©AlphaMed Press 2015




MiSOT-I [7] is a phase I, dose-escalation, safety, and feasibility
study of MAPC therapy after liver transplantation in patients
receiving living-relatedor dead-before-donation unrelateddonor
grafts (clinicaltrials.gov identifier, NCT01841632; trial details
available at: http://www.misot.eu). The primary endpoint is
acute toxicity gauged by a previously established toxicity score
[6]. The secondary endpoints are the time to biopsy-proven acute
Figure 1. Characteristics ofmultipotent adult progenitor cells (MAPCs). (A):Gating strategy for live CD452CD44+ CD90+ CD166+ CD29+ CD105+
MAPC. (B): Expression of cell surface markers typical of mesenchymal stem cells by MAPCs. (C): Absence of ABO or Lutheran blood group (not
shown) antigens. The absence of CD235a (glycophorin A), blood group A antigen, and CD239 (basal cell adhesion molecule) expression means
that MAPCs should not be susceptible to complement-mediated lysis on administration to patients with antibodies against these antigens.
Abbreviations: EGFR, epidermal growth factor receptor; HLA, human leukocyte antigen; MAPC, multipotent adult progenitor cell.
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rejection and evidence that MAPCs do not cause or promote
malignancy.
MAPC Storage
MAPC cryobags (1.53 108 cells in 18ml of PlasmaLyte-A) (Baxter
Healthcare Corp., Deerfield, IL, http://www.baxter.com) were
shipped to and stored at our clinical site according to validated
protocols. Cryopreserved MAPCs remain viable for at least
2 years, allowingMAPC therapy to be integrated into existing dis-
pensing chains with cryostorage facilities [8].
MAPC infusion
MAPCswere injected into the portal vein under direct visualization
in theoperating room(day0)andbycentral venous infusion (day2).
Immunohistochemistry
Liver biopsy sections were fixed (ice-cold acetone, 8 minutes)
and blocked (30 minutes) at room temperature (RT) using 10%
heat inactivated species-specific serum and 1:10 anti-human
FcR-blocking reagent (MiltenyiBiotec,BergischGladbach,Germany,
http://www.miltenyibiotec.com). After washing, the samples were
stained for 1 hour at RT in phosphate-buffered saline containing
0.1% bovine serum albumin using 1:100 monoclonal anti-human
leukocyte antigen (HLA)-A*03 antibody (Abcam, Cambridge, U.K.,
http://www.abcam.com). The samples were washed and incu-
bated with goat 1:100 anti-mouse IgG (Abcam) at RT. After wash-
ing, the sections were incubated with 1:500 Cy3-labeled donkey
anti-goat IgG (Invitrogen, Carlsbad, CA, http://www.invitrogen.
com). Images were captured using a Zeiss Axio Observer micro-
scope and Zeiss Axiovision 4.04 (Carl Zeiss, Jena, Germany,
http://www.zeiss.com).
Recipient Leukocyte Characterization
Peripheral blood leukocyte frequencies were monitored at fre-
quent intervals after transplantation andMAPC infusion to estab-
lish a high-granularity description of the immunological changes
that occurred. The standardized methods used for this immune
monitoring study have been previously described [9].
Figure 2. Overview of liver function test results and immunosuppressive treatment. Living-related liver transplantationwas conducted on day 0.
The patient received standard “bottom-up” pharmacological immunosuppression: intraoperativemethylprednisolone (500mg) with subsequent
postoperative tapering (starting with 1 mg/kg/day), MMF (2 g/day), and basiliximab (20 mg/kg, days 0 and 4). MAPCs were administered on
day0 (day of transplantation) intraportally and onpostoperative day 2. ALT levels peaked onday 2 (1,191.5U/l); the levels rapidly decreased and
had stabilized fromday 12 (168.0 U/l). On day 4, the patient becamemildly thrombocytopenic and leukopenic; therefore, fromday 8,MMFwas
reduced to 1.5 g/day and subsequently reduced to 1 g/day from day 10 onward. From day 5, the bilirubin and factor V levels increased; a sus-
pected acute rejectionwasdiagnosed onday6.Methylprednisolone (500mg)was administered ondays 8, 9, and 12. Cyclosporine (300mg/day)
was started on day 7with initial trough levels of 43 ng/ml (measured directly before themorning dose). Because of the subclinical cyclosporine
trough levels, the patient was switched to tacrolimus on day 15; a desired trough level of∼10 ng/mlwas achieved. The liver function test results
normalizedover thenext days. Bilirubin returned topretransplant levels fromday11, and factorV levels had stabilized fromday9and showedno
additional increase. Abbreviations: ALT, alanine aminotransferase; MAPC, multipotent adult progenitor cell; MMF, mycophenolate mofetil.
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RESULTS
MAPC Characterization
MAPCs are adherent viable adult stem cells ∼15 mm in spherical
diameter [10]. MiSOT-I uses a commercial MAPC product, Multi-
Stem (Athersys Inc., Cleveland, OH, http://www.athersys.com).
MAPC surface marker analysis showed phenotypic features that
are, in part, shared with MSCs (Fig. 1A, 1B). Because of the recip-
ient’s positive anti-Lu(b) status, the MAPCs were typed for basel
cell adhesion molecule (BCAM), Lu(b), and glycophorin A expres-
sion using flow cytometry. MAPCs expressed neither the ABO
blood group antigens nor the Lu(b) antigen (Fig. 1C).
Case Report
The local ethics committee approved theMiSOT-I protocol, which
conforms to the Declaration of Helsinki. The patient provided
written informed consent before taking part in the study.
Living-related allograft liver transplantation (donor right lobe)
was completed according to center practice. In preparation
for the intravenous infusion, a single MAPC cryobag containing
1.5 3 108 MAPCs was thawed (37°C) and combined with 18 ml
of PlasmaLyte-A infusion solution. After allograft reperfusion,
the cell suspensionwas injectedunder direct vision into theportal
vein approximately 15 mm proximal to the anastomosis using a
syringe and needle. Cell infusion (flow rate, 5 ml/min) was with-
out acute cardiocirculatory, renal, pulmonary, or other systemic
complications. Doppler ultrasonography of the portal vein before
and after MAPC injection showed appropriate postoperative flow
patterns and no evidence of thrombosis or stenosis. In addition to
the cellular therapy, immunosuppressive treatment followed a
“bottom-up” regimen: 2 g of mycophenolate mofetil (MMF) per
day; basiliximab (interleukin-2 receptor-blocking antibody) at days
0 and 4; and methylprednisolone, beginning with 1 mg/kg body
weightperday, taperedoff fromday3.Biliaryreconstructionwasper-
formed the next day. On day 2, the patient experienced atrial fibril-
lationthat respondedtoelectrical cardioversion.Thiswasreportedas
a serious adverse event (SAE) unrelated to MAPC use. The alanine
aminotransferase (ALT) levels peaked on day 2 (1,191.5 U/l),
subsequently normalizing by day 12 (168.0 U/l; Fig. 2).
A second dose of 1.53 108MAPCswas administered on day 2
by central venous infusion without acute clinical complications.
The patient became mildly thrombocytopenic and leukopenic
on day 4; therefore, MMF was reduced (1.5 g/day from day 8,
1 g/day from day 10). On day 5, biliary leakage occurred and re-
quired surgical intervention, which was reported as an SAE unre-
lated to MAPC use. From day 5, the bilirubin and factor V levels
increased, although the transaminases remained stable (Fig. 2).
Consequently, suspected acute rejection was clinically diagnosed
on day 6 and reported as an SAE unrelated to MAPC use. Persis-
tent coagulative impairment prevented a confirmatory liver
biopsy; therefore, the secondary endpoint of the time to
biopsy-proven acute rejection could not be assessed. The clini-
cally diagnosed rejection episode was successfully managed with
cyclosporine and methylprednisolone (500 mg on days 8, 9, and
12) treatment. Because of subtherapeutic cyclosporine trough
levels (for reasons unknown), immunosuppressive calcineurin in-
hibitor treatment was switched to tacrolimus. The preoperative
creatinine was normal (creatinine, 0.61 mg/dl; urea, 30 mg/dl);
however, after the introduction of tacrolimus, the creatinine lev-
els increased (peak creatinine, 1.59 mg/dl; urea, 71 mg/dl). The
patient left the intensive care unit on day 8 and was discharged
from the unit on day 43. At day 72, the patient’s first routine out-
patient visit, he presentedwith normal liver function (ALT, 51U/l;
bilirubin, 0.9 mg/dl) and normal leukocyte counts (4.93 cells per
nl) and reported he was in a positive frame of mind. For reasons
unknown, his platelet counts remained relatively low (74 cells
per nanoliter). The creatinine (1.40 mg/dl) and urea (48 mg/dl)
levels remained moderately elevated. On study day 219, the
patient experienced a Banff-rejection activity index (RAI) score
3 biopsy-confirmed acute rejection episode and was treated
with a short course of methylprednisolone. This was reported
as a SAE not related to the study product. At the latest follow-
up visit, the patient was well and had returned to his previous
daily routine.
Treatment-Emergent Adverse Events
MiSOT-I uses a toxicity scoring system to quantify treatment-
emergent adverse events (TEAEs), which has been previously de-
scribed [6]. In brief, the toxicity score is calculated from three
independent parameters reflecting potentially critical aspects
Figure 3. Biodistribution of multipotent adult progenitor cells in
liver allograft biopsies. (A–D):Control using secondand third antibod-
ies only. (E–H):HLA-A*03. Fluorescent immunostaining of liver biopsy
cryosections using anti-actin (green; B, F), anti-HLA-A*03 (red; C, G),
and DAPI (blue). (A, E):Wide-field views of anti-actin, anti-HLA-A*03,
and DAPI treated samples. (D, H): Superimposed images. Magnified
images were obtained using a320 objective from the box area indi-
cated (A, E). Scale bars = 50mm. Abbreviations: DAPI, 49,6-diamidino-
2-phenylindole; HLA, human leukocyte antigen.
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of cellular therapy: intraportal/infusional toxicity (by Doppler ul-
trasonography), pulmonary toxicity, and systemic toxicity.We
detected no severe TEAEs (defined as a score of 3) and 2 interme-
diate TEAEs (day 3 with a score of 1 and day 29 with a score of 1).
Both intermediate TEAEs resulted from a biphasic flow pattern in
the hepatic veins that predated surgery and had varied throughout
his hospitalization. During the 30-day follow-up observation period,
the portal vein (site of injection) showed appropriate flow patterns
without signs of stenosis or thrombosis. Additionally, no clinical
evidencewas found of a lung embolismafter intravenous injection.
MAPC Intragraft Biodistribution
Liver biopsy samples were obtained before reperfusion and
shortly after cell infusion to describe the parenchymal biodistri-
bution of the infused cells. MAPCs in the recipient liver tissue
were visualized by immunohistochemical staining for HLA-
A*03, anHLA class I allele expressed by the infusedMAPCproduct
but not by donor and recipient cells. The preinfusion tissue sam-
ples were negative for HLA-A*03-specific staining (data not
shown). Single HLA-A*03-positive cells of a phenotype and size
consistent with MAPCs were detected in the postinfusion sam-
ples (Fig. 3), making it likely that the infused cells were present
in the liver parenchyma at that point.
Recipient Leukocyte Profile
To characterize the recipient’s immunological response to trans-
plantation andMAPC infusion, serial analyses of peripheral blood
leukocyte subsets were performed by flow cytometry in the peri-
operative period (supplemental online Fig. 1). Overall, these data
give the impression of early activation of the innate and adaptive
immune system.Notably, the frequency of CD4+ FoxP3+ CD127low
regulatory T cells was markedly increased on day 3 after the
second MAPC infusion (Fig. 4A). In addition, downregulation of
HLA-DR expression by CD14+monocytes relative to pretransplant
levels was observed on days 1 and 3, which has previously been
associated with diminished immunological reactivity (Fig. 4B).
However, these observations should not be interpreted as evi-
dence of clinical efficacy of the cell product at this early stage
of investigation.
DISCUSSION
Wehavedescribed the first living-related liver recipient to receive
MAPCs after transplantation. MAPC administration was feasible
in both the operating room and the intensive care unit setting.
Immunohistochemistry revealed the presence of MAPCs within
the graft after infusion. No severe TEAEs were observed, and
no other evidence was seen of acute complications associated
with MAPC infusion. To date, the patient has experienced four
SAEs (atrial fibrillation, bile leakage, abnormal liver function,
and acute rejection) that were judged unrelated to the MAPC in-
fusion. The patient experienced a suspected acute rejection epi-
sode that began on day 5 after transplantation. This SAE was not
attributed to MAPC treatment, despite its close temporal rela-
tionship to the cell infusion, because acute rejection can be
expected in this time frame when low-dose induction therapy
is used. A Banff-RAI grade 3 biopsy-confirmed acute rejection ep-
isode occurred 6months later and coincided with a common cold
infection. We will continue to perform detailed assessments of
any future rejection events experienced by the study cohort. El-
evated creatinine values correlated with the tacrolimus plasma
levels, underlining the general need to reduce calcineurin inhib-
itor therapy because it is a prime objective of the present
approach.
Figure4. Monitoringofperipheral blood leukocyte subsets afterMAPCadministrationand liver transplantation. (A):FrequencyofCD4+ FoxP3+
CD127low regulatory T cells (Tregs) after transplantation. Compared with pretransplant frequencies, an increase in Treg frequency within the
peripheral blood CD4+ T-cell poolwas observed. (B):HLA-DR expression by CD45+ CD14+ peripheral bloodmonocytes. Comparedwith pretrans-
plant levels, a relative decrease in HLA-DR expressionwas observed on days 1 and 3 after transplantation. Abbreviations: %Max., percentage of
maximum; HLA, human leukocyte antigen.
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CONCLUSION
This first-in-human case study has demonstrated that intraportal
and intravenous infusion of third-party MAPCs after liver trans-
plantation is clinically feasible. The absence of any acute clinical
complications of the cell infusion is reassuring for future admin-
istration of MAPCs. Recruitment and follow-up of participants in
the MiSOT-I trial continue, and completion of the study is cur-
rently projected for autumn 2016.
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